Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma

被引:286
作者
Ma, J
Mai, HQ
Hong, MH
Min, HQ
Mao, ZD
Cui, NJ
Lu, TX
Mo, HY
机构
[1] Sun Yat Sen Univ Med, Ctr Canc, Dept Nasopharyngeal Carcinoma, Guangzhou 510060, Peoples R China
[2] Sun Yat Sen Univ Med, Ctr Canc, Dept Radiat Oncol, Guangzhou 510060, Peoples R China
关键词
D O I
10.1200/JCO.2001.19.5.1350
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: A prospective randomized trial was performed to evaluate the contribution of neoadjuvant chemotherapy in patients with to locoregionally advanced nasopharyngeal carcinoma. Patients and Methods: patients with locoregionally advanced nasopharyngeal carcinoma were treated either with radiotherapy alone (RT group) or neoadjuvant chemotherapy plus radiotherapy (CT/RT group). Neoadjuvant chemotherapy consisting of two to three cycles of cisplatin (100 mg/m(2), day 1), bleomycin (10 mg/m(2), days 1 and 5), and fluorouracil (5-FU; 800 mg/m(2), days 1 through 5, continuous infusion) followed by radiotherapy was given to the CT/RT group. All patients were treated in a uniform fashion by definitive-intent radiation therapy in both groups. Results: between July 1993 and July 1994, 456 patients were entered onto the study, with 228 patients randomised to each treatment arm, and 449 patients (225 in the RT group and 224 in the CT/RT group) were assessable. All 456 patients were included in survival analysis according to the intent-to-treat principle. The 5-year overall survival (OS) rates were 63% for the CT/RT group and 56% for the RT group (P = .11). The median relapse-free survival (RFS) time was 50 months for the RT group and not reached for the CT/RT group. the 5-year RFS rate was 49% for the RT group versus 59% for the CT/RT group (P = .05). The 5-year freedom from local recurrence rate was 82% for the CT/RT group and 74% for the RT group (P = .04). There was no significant difference in freedom from distant metastasis between the two treatment groups (CT/RT group, 79%; RT group, 75%; P = .40). Conclusion: This randomized study failed to demonstrate any significant survival benefit with the addition of neoadjuvant chemotherapy for patients with locoregionally advanced nasopharyngeal carcinoma. Therefore, neoadjuvant chemotherapy for nasopharyngeal carcinoma should not be used outside of the context of a clinical trial. J Clin Oncol 19:1350-1357. (C) 2001 by American Society of Clinical Oncology.
引用
收藏
页码:1350 / 1357
页数:8
相关论文
共 41 条
[21]   RETROSPECTIVE ANALYSIS OF 5037 PATIENTS WITH NASOPHARYNGEAL CARCINOMA TREATED DURING 1976-1985 - OVERALL SURVIVAL AND PATTERNS OF FAILURE [J].
LEE, AWM ;
POON, YF ;
FOO, W ;
LAW, SCK ;
CHEUNG, FK ;
CHAN, DKK ;
TUNG, SY ;
THAW, M ;
HO, JHC .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 23 (02) :261-270
[22]  
Luo W, 1996, CHINESE J CANC, V15, P280
[23]  
MA J, 1998, CHINESE J CANC, V18, P44
[24]  
MAHJOUBI R, 1992, P ASCO, V11, P240
[25]  
MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO
[26]  
2-6
[27]  
MIN HQ, 1994, INT J RADIAT ONCOL, V30, P1037
[28]  
MIN HQ, 1996, EPIDEMIOLOGY, P280
[29]   CARCINOMA OF THE NASOPHARYNX - FACTORS AFFECTING PROGNOSIS [J].
PEREZ, CA ;
DEVINENI, VR ;
MARCIALVEGA, V ;
MARKS, JE ;
SIMPSON, JR ;
KUCIK, N .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 23 (02) :271-280
[30]   ACUTE AND LATE TOXICITY ASSOCIATED WITH SEQUENTIAL BLEOMYCIN-CONTAINING CHEMOTHERAPY REGIMENS AND RADIATION-THERAPY IN THE TREATMENT OF CARCINOMA OF THE NASOPHARYNX [J].
PETERS, LJ ;
HARRISON, ML ;
DIMERY, IW ;
FIELDS, R ;
GOEPFERT, H ;
OSWALD, MJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1988, 14 (04) :623-633